Takeda expands PRA partnership to Japan

Takeda Pharmaceutical (TYO: 4502) and the USA’s PRA Health Sciences (Nasdaq: PRAH) have agreed to a new partnership to expand their global relationship initially disclosed in September 2016 to include Japan.

Japan’s largest drugmaker Takeda and PRA will establish a joint venture, each holding 50％ of the share respectively, to provide clinical trial delivery and pharmacovigilance services as a strategic partner of Takeda in Japan. Takeda also will transfer all of the shares of Takeda Pharmaceutical Data Services (TDS), a wholly-owned subsidiary of Takeda, to PRA. This partnership is another step in Takeda’s transformation of its global R&D organization by providing access to a more flexible operational capability to support development, as well as further globalizing Takeda Development Center Japan, based in Osaka.

In alignment with Takeda's global R&D strategy, the newly-established joint venture will leverage its internal resources and expertise to manage an entire portfolio of studies for Takeda, across Phases I-IV, and provide pharmacovigilance and other operational services for both development and marketed product portfolios in close alignment with Takeda Development Center Japan.